<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405170</url>
  </required_header>
  <id_info>
    <org_study_id>B0121008</org_study_id>
    <nct_id>NCT01405170</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions</brief_title>
  <official_title>Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 mg/mL To Methylprednisolone 32 mg Tablet Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine whether a new formulation of methylprednisolone suspension is
      bioequivalent to methylprednisolone tablets under fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf (area under the concentration time curve to infinity)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast (area under the concentration time curve to last time point)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (time at maximum concentration)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Therapeutic Equivalency</condition>
  <arm_group>
    <arm_group_label>methylprednisolone suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>constituted powder for oral suspension 4 mg/mL single dose at 32 mg</description>
    <arm_group_label>methylprednisolone suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>tablets 32 mg single dose</description>
    <arm_group_label>methylprednisolone tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects between the ages of 21 and 55 years.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight &gt; 45 kg (99 lbs).

        Exclusion Criteria:

          -  Any condition possible affecting drug absorption (eg, gastectomy).

          -  A positive urine drug screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0121008&amp;StudyName=A%20Bioequivalence%20Study%20Comparing%20Methylprednisolone%20Suspension%20to%20Methylprednisolone%20Tablets%20Under%20Fed%20Conditions</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>October 25, 2011</last_update_submitted>
  <last_update_submitted_qc>October 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence study</keyword>
  <keyword>methylprednisolone</keyword>
  <keyword>suspension</keyword>
  <keyword>tablets</keyword>
  <keyword>fed</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

